Crosstalk between ferroptosis and the epithelial-mesenchymal transition: Implications for inflammation and cancer therapy |
| |
| Institution: | 1. Division of Genetics, Department of Cell and Molecular & Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran;2. Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran;3. Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran;4. Department of Chemistry and Biochemistry, South Dakota State University (SDSU), Brookings, SD, USA;5. Department of Genetics, Faculty of Basic Sciences, Shahrekord University, Iran;6. Depatment of Biology, Faculty of Science, Islamic Azad University, Kerman, Iran;7. Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa;8. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA;9. Department of Anatomy, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran;10. Department of Biology, Faculty of Basic Sciences, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran;1. Genetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Iran;2. Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran;3. Department of Cellular and molecular, School of Biological Sciences, Islamic Azad University of Falavarjan, Iran;4. Biotechnology department of Fasa University of medical science, Fasa, Iran;5. Department of Biology, Faculty of Science, University Of Isfahan, Isfahan, Iran;6. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran;7. Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran;8. Department of Genetics, Faculty of Basic Sciences, Shahrekord University, Iran;9. Department of Biological Science and Technology, Faculty of Nano and Bio Science and Technology, Persian Gulf University, Bushehr 75169, Iran;10. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA;1. Genetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Iran;2. Department of Anesthesiology and Critical Care Medicine, University of Tehran, Tehran, Iran;3. Department of Microbiology, Islamic Azad University of Jahrom, Fars, Iran;4. Division of Biotechnology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran;5. Medical School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran;6. Kurdistan Immunology & Hematology Research Center, Kurdistan University of Medical Science, Sanandaj, Iran;7. Stem Cell Research Center and Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran;8. Department of Biology, Faculty of Science, University Of Isfahan, Isfahan, Iran;9. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran;10. Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran;11. Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa;12. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA;1. Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272, United Arab Emirates;2. College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates;3. College of Medicine, University of Sharjah, Sharjah, 27272, United Arab Emirates;1. Cell Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA;2. BCMB Allied Program, Weill Cornell Graduate School of Medical Sciences, 1300 York Ave., New York, NY 10065, USA;1. Anhui Province Key Laboratory of Translational Cancer Research, Bengbu Medical College, Anhui 233030, China;2. Department of Clinical Medicine, Bengbu Medical College, Anhui 233030, China;3. Department of Life Sciences, Bengbu Medical College, Anhui 233030, China |
| |
| Abstract: | Both genomic instability and the presence of chronic inflammation are involved in carcinogenesis and tumor progression. These alterations predispose the cancer cells to undergo metabolic reprogramming as well as the epithelial-mesenchymal transition (EMT). These pathways allow cancer cells to avoid apoptosis and stimulate tumor progression. EMT is an important early event in tumor cell invasion, which can be regulated through inflammatory signaling pathways. Cancer cells undergoing EMT are vulnerable to cell death by the process of ferroptosis. Ferroptosis is a form of regulated cell death involving iron-dependent lipid peroxidation, designed to maintain cellular homeostasis. Several reports have linked ferroptosis, inflammation, and cancer. Ferroptosis inhibitors and EMT inducers have been used to understand the anti-inflammatory and anticancer effects in experimental models. A better understanding of the crosstalk between ferroptosis and EMT, and the involvment of inflammatory mediators may accelerate the discovery of therapeutic strategies to eradicate cancer cells and overcome drug-resistance. |
| |
| Keywords: | Cancer cells Ferroptosis EMT Inflammation Cancer therapy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
